STOCK TITAN

Incyte Genomics (INCY) Stock News, Mar-Apr 2023

INCY NASDAQ

Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.

Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.

Rhea-AI Summary

MorphoSys and Incyte presented final five-year follow-up data from the Phase 2 L-MIND study at the American Association for Cancer Research Annual Meeting 2023. The study focused on the effectiveness of Monjuvi, an immunotherapy, combined with lenalidomide, in treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Key findings included an overall response rate of 57.5%, with a complete response in 41.2% of patients. Importantly, the median overall survival was reported at 33.5 months. No new safety concerns arose, with most adverse events being grade 1 or 2. This data reinforces Monjuvi's potential as a viable treatment option for patients who are not candidates for autologous stem cell transplants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
-
Rhea-AI Summary

Incyte (NASDAQ:INCY) has announced its conference call and webcast scheduled for May 2, 2023, at 8:00 a.m. ET to discuss its Q1 2023 financial results. The press release for these results will be available earlier that day at 7:00 a.m. ET. Investors can access the call via domestic and international dial-in numbers or through an online webcast at Investor.Incyte.com. A replay of the conference call will be accessible for 30 days following the event. Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware, dedicated to addressing serious unmet medical needs through the development of innovative therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
conferences earnings
-
Rhea-AI Summary

Incyte announced that the Japanese Ministry of Health, Labour and Welfare has approved Pemazyre (pemigatinib) for treating myeloid/lymphoid neoplasms (MLNs) with FGFR1 fusion. This marks a significant step in providing a treatment option for Japanese patients with this rare cancer, affecting fewer than 100 people worldwide. The approval is based on the Phase 2 FIGHT-203 study, which showed a 62.5% complete response rate among 41 patients. Pemazyre previously received Orphan Drug Designation for rare diseases. It’s also the first targeted treatment for relapsed MLNs with FGFR1 rearrangement in the U.S., showcasing Incyte's commitment to addressing critical medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
Rhea-AI Summary

Incyte (Nasdaq: INCY) announced the U.S. FDA issued a complete response letter regarding the New Drug Application (NDA) for ruxolitinib extended-release (XR) tablets. The FDA did not approve the application in its current form, though acknowledged the NDA met bioequivalence objectives. Incyte plans to engage with the FDA to clarify the necessary steps for approval. CEO Hervé Hoppenot expressed disappointment but reaffirmed commitment to support patients with myeloproliferative neoplasms and graft-versus-host disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
none
-
Rhea-AI Summary

Incyte announced FDA approval of Zynyz (retifanlimab-dlwr) for treating adults with metastatic or locally advanced Merkel cell carcinoma (MCC). This marks the first regulatory approval of a PD-1 inhibitor based on the POD1UM-201 trial results, which showed a 52% objective response rate among chemotherapy-naïve patients. The approval was granted under accelerated conditions, potentially subject to further validation of clinical benefits. Zynyz is also being studied for other tumor types and in combination therapies. Serious adverse reactions occurred in 22% of patients, with fatigue and arrhythmia being the most common.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
-
Rhea-AI Summary

Incyte announced promising results from a Phase 2b trial of povorcitinib, an oral JAK1 inhibitor, for treating extensive nonsegmental vitiligo. Presented at the 2023 AAD Annual Meeting, the trial showed statistically significant improvements in total body and facial repigmentation at Week 24. The primary endpoint demonstrated a mean decrease in T-VASI scores: -19.1% for 15 mg, -17.8% for 45 mg, and -15.7% for 75 mg compared to a +2.3% increase in the placebo group (p0.01). The treatment was generally well tolerated, with no serious adverse events related to the drug, underscoring its potential as an effective therapeutic option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
Rhea-AI Summary

Incyte announced new results from the Phase 3 TRuE-V clinical trial program evaluating Opzelura (ruxolitinib) in patients with nonsegmental vitiligo. At Week 104, patients who had a high level of facial repigmentation maintained a durable response a year after treatment withdrawal. Continued treatment led to further improvements in facial and total body repigmentation. The results, presented at the 2023 American Academy of Dermatology Annual Meeting, indicate Opzelura's efficacy and safety, as well as its potential as a long-term treatment option for vitiligo.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
-
Rhea-AI Summary

Incyte (NASDAQ:INCY) has announced multiple abstracts that will be presented during the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place from April 14-19 in Orlando, Florida. Key presentations include findings on pemigatinib in previously-treated solid tumors and five-year results from the L-MIND study of tafasitamab in DLBCL. Notable oral presentations include insights into the development of INCB123667 for breast cancers, as well as the final results of tafasitamab. The meeting will allow virtual access to on-demand sessions until July 19, 2023. For more details, visit the AACR website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
none
-
Rhea-AI Summary

Caris Life Sciences announced a strategic research partnership with Incyte Corporation on March 7, 2023, to enhance precision medicine approaches for Incyte's oncology pipeline. This partnership leverages Caris' advanced molecular science solutions, including comprehensive profiling and AI capabilities, to improve patient outcomes. Initially focusing on two therapeutic programs, Incyte has the option to expand to four. This collaboration aims to optimize clinical trial strategies and discover novel biomarkers, reinforcing Incyte's commitment to developing innovative cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
partnership
Rhea-AI Summary

Incyte announced the presentation of new long-term data from the Phase 3 TRuE-V trials for Opzelura (ruxolitinib) cream, focused on vitiligo, at the upcoming 2023 AAD Annual Meeting in New Orleans. Two late-breaking oral presentations will detail durability and long-term response, with safety and efficacy data from a Phase 2b study of povorcitinib (INCB54707) also highlighted. Incyte will host an in-person event on March 18, 2023, to discuss these key findings. Opzelura is the first FDA-approved treatment for repigmentation in nonsegmental vitiligo and shows promise for other dermatological conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.20%
Tags
none

FAQ

What is the current stock price of Incyte Genomics (INCY)?

Incyte Genomics (INCY) last closed at $119.09.

What is the market cap of Incyte Genomics (INCY)?

The market cap of Incyte Genomics (INCY) is approximately $24.3B.